Bulletin
Investor Alert

New York Markets Close in:

Oct. 18, 2021, 11:37 a.m. EDT

CLASS ACTION UPDATE for SESN, HYRE and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Sesen Bio Inc. (SESN)
  • X
    HyreCar Inc. (HYRE)
  • X
    Boston Beer Co. Cl A (SAM)

or Cancel Already have a watchlist? Log In

October 18, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / October 18, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SESN Shareholders Click Here: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20500&wire=1

HYRE Shareholders Click Here: https://www.zlk.com/pslra-1/hyrecar-inc-loss-submission-form?prid=20500&wire=1

SAM Shareholders Click Here: https://www.zlk.com/pslra-1/the-boston-beer-company-inc-loss-submission-form?prid=20500&wire=1

* ADDITIONAL INFORMATION BELOW *

Image: https://www.accesswire.com/users/newswire/images/668552/Rotating-Logo.jpg

Sesen Bio, Inc. /zigman2/quotes/201402704/composite SESN +0.52%

SESN Lawsuit on behalf of: investors who purchased December 21, 2020 - August 17, 2021

Lead Plaintiff Deadline: October 18, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20500&wire=1

According to the filed complaint, during the class period, Sesen Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

HyreCar Inc. /zigman2/quotes/200312721/composite HYRE +3.81%

HYRE Lawsuit on behalf of: investors who purchased May 14, 2021 - August 10, 2021

Lead Plaintiff Deadline: October 26, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/hyrecar-inc-loss-submission-form?prid=20500&wire=1

According to the filed complaint, during the class period, HyreCar Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) HyreCar had materially understated its insurance reserves; (b) HyreCar had systematically failed to pay valid insurance claims incurred prior to the Class Period; (c) HyreCar had incurred significant expenses transitioning to its new third-party insurance claims administrator and processing claims incurred from prior periods; (d) HyreCar had failed to appropriately price risk in its insurance products and was experiencing elevated claims incidence as a result; (e) HyreCar had been forced to dramatically reform its claims underwriting, policies and procedures in response to unacceptably high claims severity and customer complaints; and (f) as a result, HyreCar's operations and prospects were misrepresented because the Company was not on track to meet the financial estimates provided to investors during the Class Period, and such estimates lacked a reasonable basis in fact, including HyreCar's purported gross margin, EBITDA (earnings before interest, taxes, depreciation, and amortization), and net loss trajectories.

The Boston Beer Company, Inc. /zigman2/quotes/205338227/composite SAM +4.47%

SAM Lawsuit on behalf of: investors who purchased April 22, 2021 - September 8, 2021

/zigman2/quotes/201402704/composite
US : U.S.: Nasdaq
$ 0.53
+0.0027 +0.52%
Volume: 2.47M
May 27, 2022 3:37p
P/E Ratio
2.06
Dividend Yield
N/A
Market Cap
$104.18 million
Rev. per Employee
$635,257
loading...
/zigman2/quotes/200312721/composite
US : U.S.: Nasdaq
$ 1.09
+0.04 +3.81%
Volume: 76,496
May 27, 2022 3:37p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$22.89 million
Rev. per Employee
$497,608
loading...
/zigman2/quotes/205338227/composite
US : U.S.: NYSE
$ 358.00
+15.31 +4.47%
Volume: 78,968
May 27, 2022 3:38p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.21 billion
Rev. per Employee
$763,922
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.